Thomas E. Timbie - 17 May 2022 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Reporting relationship: Director
Issuer ticker: TMCI
Reported as of: 17 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2022, 20:38:12 UTC
Prior SEC filing: 10 Mar 2022
Next SEC filing: 05 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Lisa Taylor as Attorney-in-fact for Thomas Timbie

Key filing fact

Thomas E. Timbie filed Form 4 for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 19 May 2022.

Key facts

This page summarizes Thomas E. Timbie's Form 4 filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 May 2022, 20:38.

Change

Previous filing in this sequence was filed on 10 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMCI transaction

Common Stock

Award

Transaction value: $0
Shares: +2,295
Change %
Price: $0.000000
Shares after: 2,295
Date: 17 May 2022
Ownership: Direct
Footnotes: F1

TMCI transaction

Common Stock

Gift

Transaction value: $0
Shares: -120,000
Change %: -24%
Price: $0.000000
Shares after: 385,000
Date: 09 May 2022
Ownership: Pamela Timbie and Thomas Timbie as Trustees of the PAMELA F TIMBIE REV TRUST

TMCI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,649,069
Date: 17 May 2022
Ownership: Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TMCI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +16,625
Change %
Price: $0.000000
Shares after: 16,625
Date: 17 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,625
Exercise price: $15.80
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on May 17, 2023 subject to Reporting Person's providing continued service to Issuer through the vesting date.

Footnote F2

The stock option will vest in 12 substantially equal monthly installments, commencing on June 17, 2022, such that the stock option will be fully vested and exercisable on May 17, 2023, subject to Reporting Person's providing continued service to Issuer through each vesting date.